Agendia to Collaborate with MD Anderson, Netherlands Institute to Further Validate ColoPrint | GenomeWeb

Originally published June 13.

By Turna Ray

Agendia will deploy
its ColoPrint colon cancer recurrence test in a collaboration with MD Anderson Cancer Center and the Netherlands Cancer Institute intended to further understand the molecular pathways driving the disease. The study will also yield additional validation data on ColoPrint that, if positive, will likely bolster the regulatory and reimbursement prospects for the test in the US.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.